Organisation paid for research Program year 2025 Source: CMS Open Payments

Trinity Health Michigan

Neither a doctor nor a teaching hospital

Research payments

$656,643

146 payments

Through program year 2025, Trinity Health Michigan is reported as receiving $656,643 in research payments, across 146 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $167,530 26
2024 Research $161,190 26
2023 Research $59,226 10
2022 Research $27,756 11
2021 Research $57,896 24
2020 Research $57,209 19
2019 Research $125,836 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $262,386 9 payments
  2. Abbott Laboratories $157,867 65 payments
  3. AbbVie, Inc. $154,100 44 payments
  4. Boston Scientific Corporation $19,549 11 payments
  5. Epizyme, Inc., $16,000 3 payments
  6. Pharmacyclics LLC, An AbbVie Company $14,806 2 payments
  7. Novocure Inc. $13,750 3 payments
  8. Medical Device Business Services, Inc. $11,715 5 payments
  9. Ucb SA $3,200 1 payment
  10. Novartis Pharmaceuticals Corporation $3,120 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $168,446 4 payments
  2. A Randomized Phase 2 Trial of Am0010 in Combination With Pembrolizumab VS. Pembrolizumab Alone As First-Line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Have High Pd-L1 Expression $71,646 2 payments
  3. A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $67,230 16 payments
  4. A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. $31,725 6 payments
  5. A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma $25,390 3 payments
  6. A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. $22,679 5 payments
  7. A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma $21,477 6 payments
  8. Preempt HF $19,549 11 payments
  9. Assert-IQ Insertable Cardiac Monitor Post Market Study $19,349 4 payments
  10. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) $17,424 4 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $13,750 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record